These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men.
    Author: Føgh M, Corker CS, Hunter WM, McLean H, Philip J, Schou G, Skakkebaek NE.
    Journal: Acta Endocrinol (Copenh); 1979 Jul; 91(3):545-52. PubMed ID: 474042.
    Abstract:
    One daily dose of either 5 mg or 10 mg cyproterone acetate (CA) was administered to 2 groups of 4 fertile men for 6 months. The medication was preceded by a 3 months placebo period and followed by a recovery phase of 5 to 8 months. During CA-treatment the sperm count/ml decreased and the percentage of abnormal spermatozoa increased slightly (0.991 less than P less than 0.05). Sperm penetration assessed by the Kremer test did not show any decrease during treatment. Serum levels of testosterone and FSH decreased, but those of LH remained unchanged during treatment. Two pregnancies occurred after 13/4 and 51/2 months of CA-treatment. The serum-CA concentration in these 2 volonteers did not differ from that of the remainder. Three subjects who began the study were withdrawn because of depressive mood changes (2) and weakness combined with dizziness (1). Data from these subjects were not included. The results indicate that daily doses of 5 mg and 10 mg of cyproterone acetate are not effective as a male contraceptive. 1 daily dose of either 5 mg or 10 mg cyproterone acetate (CA) was administered to 2 groups of 14 fertile men for 6 months in order to study the effects of low doses of CA. Semen samples were collected by masturbation at approximately 2-week intervals and analyzed for volume, sperm count and sperm morphology. Motility was evaluated subjectively by light microscopy. Sperm penetration was assessed by the Kremer Test (1965) after at least 16 weeks of treatment. General well-being, libido and sexual potency were assessed approximately every fortnight. The medication was preceded by a 3 month placebo period and followed by a recovery phase of 5-8 months. 7 volunteers completed the study. During CA treatment the sperm count/ml decreased and the percentage of abnormal spermatozoa increased slightly. Sperm penetration failed to show any decrease during treatment. Serum levels of testosterone and follicle stimulating hormone (FSH) decreased, but those of the luteinizing hormone (LH) remained unchanged during treatment. 2 pregnancies occurred after 1-3/4 and 5-1/2 months of CA treatment. The serum-CA concentration in these 2 volunteeers did not differ from that of the remainder of the volunteers. The results demonstrate that low doses of CA significantly decreased sperm count in 6 of 7 subjects but did not decrease it to the so-called "infertile" levels.
    [Abstract] [Full Text] [Related] [New Search]